Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy

American Journal of Roentgenology

Volumn 201, Issue 1, 2013, Pages 80-96

  Yaghmai, Vahid ^a   Besa, Cecilia ^b   Kim, Edward ^b   Gatlin, Joseph L ^a   Siddiqui, Nasir A ^a   Taouli, Bachir ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Ablation; CT; Hepatocellular carcinoma; MRI; Transarterial chemoembolization

Indexed keywords

ALCOHOL; BEVACIZUMAB; GADOXETIC ACID; IODINATED POPPYSEED OIL; PLACEBO; SIR SPHERES; SORAFENIB; THERASPHERES; UNCLASSIFIED DRUG; YTTRIUM 90;

CANCER SIZE; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; DISEASE MARKER; ECHOGRAPHY; HEPATOGRAPHY; HUMAN; IMAGE ENHANCEMENT; LIVER CELL CARCINOMA; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; TISSUE NECROSIS; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DIAGNOSTIC IMAGING; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC;

EID: 84883330721     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.10706     Document Type: Review

References (144)

1. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37(suppl 2):S88-S94
2. Shields A, Reddy KR. Hepatocellular carcinoma: current treatment strategies. Curr Treat Options Gastroenterol 2005; 8:457-466
3. Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr 2010; 34:479-484
4. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127(5 suppl 1):S179-S188
5. Yao FY, Hirose R, LaBerge JM, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005; 11:1505-1514
6. Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50:123-128
7. Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234:954-960
8. Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819-827
9. Mendizabal M, Reddy KR. Current management of hepatocellular carcinoma. Med Clin North Am 2009; 93:885-900, viii
10. Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 2004; 7:431-441
11. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245-1255
12. Khan KN, Yatsuhashi H, Yamasaki K, et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000; 32:269-278
13. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol 2010; 52:380-388
14. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243:321-328
15. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49:453-459
16. Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33:11-17
17. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104:514-524
18. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008; 47:82-89
19. Yu NC, Raman SS, Kim YJ, Lassman C, Chang X, Lu DS. Microwave liver ablation: influence of hepatic vein size on heat-sink effect in a porcine model. J Vasc Interv Radiol 2008; 19:1087-1092
20. Shafiee H, Garcia PA, Davalos RV. A preliminary study to delineate irreversible electroporation from thermal damage using the Arrhenius equation. J Biomech Eng 2009; 131:074509
21. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442
22. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739
23. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171
24. Lammer J, Malagari K, Vogl T, et al.; Precision V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41-52
25. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46:474-481
26. Atassi B, Bangash AK, Bahrani A, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. RadioGraphics 2008; 28:81-99
27. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127:S194-S205
28. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (Thera-Sphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16:1627-1639
29. Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66:792-800
30. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140:497-507
31. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390
32. Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18:413-420
33. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47:71-81
34. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006; 25:3866-3884
35. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48:1312-1327
36. Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45:9-15
37. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002; 36:1221-1226
38. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34
39. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304:2154-2160
40. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26:2992-2998
41. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022
42. Wilson SR, Burns PN, Muradali D, Wilson JA, Lai X. Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis. Radiology 2000; 215:153-161
43. Youk JH, Kim CS, Lee JM. Contrast-enhanced agent detection imaging: value in the characterization of focal hepatic lesions. J Ultrasound Med 2003; 22:897-910
44. Kim HJ, Kim TK, Kim PN, et al. Assessment of the therapeutic response of hepatocellular carcinoma treated with transcatheter arterial chemoembolization: comparison of contrast-enhanced sonography and 3-phase computed tomography. J Ultrasound Med 2006; 25:477-486
45. Chen MH, Wu W, Yang W, et al. The use of contrast-enhanced ultrasonography in the selection of patients with hepatocellular carcinoma for radio frequency ablation therapy. J Ultrasound Med 2007; 26:1055-1063
46. Pompili M, Riccardi L, Covino M, et al. Contrastenhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. Liver Int 2005; 25:954-961
47. Baron RL, Oliver JH 3rd, Dodd GD 3rd, Nalesnik M, Holbert BL, Carr B. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996; 199:505-511
48. Choi BI, Lee HJ, Han JK, Choi DS, Seo JB, Han MC. Detection of hypervascular nodular hepatocellular carcinomas: value of triphasic helical CT compared with iodized-oil CT. AJR 1997; 168:219-224
49. Iannaccone R, Laghi A, Catalano C, et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology 2005; 234:460-467
50. Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266:376-382
51. Silva AC, Morse BG, Hara AK, Paden RG, Hongo N, Pavlicek W. Dual-energy (spectral) CT: applications in abdominal imaging. RadioGraphics 2011; 31:1031-1046; discussion, 1047-1050
52. Zhang LJ, Peng J, Wu SY, et al. Liver virtual non-enhanced CT with dual-source, dual-energy CT: a preliminary study. Eur Radiol 2010; 20:2257-2264
53. Altenbernd J, Heusner TA, Ringelstein A, Ladd SC, Forsting M, Antoch G. Dual-energy-CT of hypervascular liver lesions in patients with HCC: investigation of image quality and sensitivity. Eur Radiol 2011; 21:738-743
54. Lee SH, Lee JM, Kim KW, et al. Dual-energy computed tomography to assess tumor response to hepatic radiofrequency ablation: potential diagnostic value of virtual noncontrast images and iodine maps. Invest Radiol 2011; 46:77-84
55. Earls JP, Rofsky NM, DeCorato DR, Krinsky GA, Weinreb JC. Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: optimization with a test examination and a power injector. Radiology 1997; 202:268-273
56. Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver. Part Protocol optimization and lesion appearance in the cirrhotic liver. AJR 2010; 195:29-41
57. Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver. Part Protocol optimization and lesion appearance in the noncirrhotic liver. AJR 2010; 195:13-28
58. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2006; 17:505-512
59. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33:532-540
60. Kierans AS, Elazzazi M, Braga L, et al. Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response. AJR 2010; 194:523-529
61. Kim S, Mannelli L, Hajdu CH, et al. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 2010; 31:348-355
62. Watanabe H, Kanematsu M, Goshima S, et al. Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy? AJR 2012; 198:589-595
63. Yoon JH, Lee EJ, Cha SS, et al. Comparison of gadoxetic acid-enhanced MR imaging versus fourphase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 2010; 21:348-356
64. Schima W, Ba-Ssalamah A, Kurtaran A, Schindl M, Gruenberger T. Post-treatment imaging of liver tumours. Cancer Imaging 2007; 7(spec no A):S28-S36
65. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32:792-797
66. Talbot JN, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006; 33:1285-1289
67. [No authors listed]. World Health Organization (WHO) handbook for reporting results of cancer treatment. Geneva, Switzerland: WHO, 1979: WHO offset publication no. 48
68. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
69. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
70. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. RadioGraphics 2008; 28:329-344
71. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711
72. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference-European Association for the Study of the Liver. J Hepatol 2001; 35:421-430
73. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60
74. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943
75. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118:147-156
76. Prajapati HJ, Spivey JR, Hanish SI, et al. mRECIST and EASL responses at early time point by contrastenhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 2012 Dec 5 [Epub ahead of print]
77. Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262:708-718
78. Kim BK, Kim KA, Park JY, et al. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 2013; 49:826-834
79. Shim JH, Lee HC, Won HJ, et al. Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. J Hepatol 2012; 56:406-411
80. Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55:1309-1316
81. Kawaoka T, Aikata H, Murakami E, et al. Evaluation of the mRECIST and alpha-fetoprotein ratio for stratification of the prognosis of advancedhepatocellular-carcinoma patients treated with sorafenib. Oncology 2012; 83:192-200
82. Kim YS, Rhim H, Lim HK. Imaging after radiofrequency ablation of hepatic tumors. Semin Ultrasound CT MR 2009; 30:49-66
83. Memon K, Kulik L, Lewandowski RJ, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011; 141:526-535
84. Virmani S, Ryu RK, Sato KT, et al. Effect of Carm angiographic CT on transcatheter arterial chemoembolization of liver tumors. J Vasc Interv Radiol 2007; 18:1305-1309
85. Lewandowski RJ, Tepper J, Wang D, et al. MR imaging perfusion mismatch: a technique to verify successful targeting of liver tumors during transcatheter arterial chemoembolization. J Vasc Interv Radiol 2008; 19:698-705
86. Nishimine K, Uchida H, Matsuo N, et al. Segmental transarterial chemoembolization with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother Pharmacol 1994; 33(suppl):S60-S68
87. Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR 2007; 188:480-488
88. Park MH, Rhim H, Kim YS, Choi D, Lim HK, Lee WJ. Spectrum of CT findings after radiofrequency ablation of hepatic tumors. RadioGraphics 2008; 28:379-390; discussion, 390-392
89. Kim SK, Lim HK, Kim YH, et al. Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. RadioGraphics 2003; 23:107-121
90. Chung WS, Lee KH, Park MS, et al. Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. AJR 2012; 199:349-359
91. Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR 2000; 175:699-704
92. Kwan SW, Fidelman N, Ma E, Kerlan RK Jr, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl 2012; 18:727-736
93. Kim HC, Chung JW, Lee W, Jae HJ, Park JH. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. RadioGraphics 2005; 25(suppl 1):S25-S39
94. Okabe N, Morimoto M, Kondo M, et al. Efficacy of chemoembolization for recurrent HCC after curative ablation therapy. Hepatogastroenterology 2012; 29:60
95. Khankan AA, Murakami T, Onishi H, et al. Hepatocellular carcinoma treated with radio frequency ablation: an early evaluation with magnetic resonance imaging. J Magn Reson Imaging 2008; 27:546-551
96. Dromain C, de Baere T, Elias D, et al. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 2002; 223:255-262
97. Lim HK, Choi D, Lee WJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 2001; 221:447-454
98. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologicpathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49:1185-1193
99. Ibrahim SM, Nikolaidis P, Miller FH, et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 2009; 34:566-581
100. Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR 2007; 188:768-775
101. Kim MJ, Choi JI, Lee JS, Park JW. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26: 1201-1206
102. Horger M, Lauer UM, Schraml C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009; 9:208
103. Faivre S, Zappa M, Vilgrain V, et al. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res 2011; 17:4504-4512
104. Tran LN, Brown MS, Goldin JG, et al. Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. Acad Radiol 2004; 11:1355-1360
105. Galizia MS, Tore HG, Chalian H, Yaghmai V. Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol 2011; 18:1555-1560
106. Yaghmai V, Miller FH, Rezai P, Benson AB 3rd, Salem R. Response to treatment series. Part Tumor response assessment: using new and conventional criteria. AJR 2011; 197:18-27
107. Chalian H, Tochetto SM, Tore HG, Rezai P, Yaghmai V. Hepatic tumors: region-of-interest versus volumetric analysis for quantification of attenuation at CT. Radiology 2012; 262:853-861
108. Alonzi R, Hoskin P. Functional imaging in clinical oncology: magnetic resonance imaging-and computerised tomography-based techniques. Clin Oncol (R Coll Radiol) 2006; 18:555-570
109. Piana G, Trinquart L, Meskine N, Barrau V, Beers BV, Vilgrain V. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol 2011; 55:126-132
110. Park MS, Kim S, Patel J, et al. Hepatocellular carcinoma: detection with diffusion-weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology 2012; 56:140-148
111. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 2007; 188:1622-1635
112. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25:4104-4109
113. Kamel IR, Bluemke DA, Ramsey D, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR 2003; 181:708-710
114. Chen CY, Li CW, Kuo YT, et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants-initial experience. Radiology 2006; 239:448-456
115. Deng J, Miller FH, Rhee TK, et al. Diffusionweighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 2006; 17:1195-1200
116. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18:49-56
117. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009; 250:466-473
118. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR 2009; 193:1044-1052
119. Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 2008; 246:812-822
120. Goshima S, Kanematsu M, Kondo H, et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 2008; 27:834-839
121. Yuan Z, Ye XD, Dong S, et al. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol 2010; 75:e9-e14
122. Mannelli L, Kim S, Hajdu CH, Babb JS, Taouli B. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: prediction and assessment of response to transarterial chemoembolization-preliminary experience. Eur J Radiol 2012 Dec 12 [Epub ahead of print]
123. Schraml C, Schwenzer NF, Clasen S, et al. Navigator respiratory-triggered diffusion-weighted imaging in the follow-up after hepatic radiofrequency ablation: initial results. J Magn Reson Imaging 2009; 29:1308-1316
124. Kim SY, Lee SS, Byun JH, et al. Malignant hepatic tumors: short-term reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. Radiology 2010; 255:815-823
125. Kim SY, Lee SS, Park B, et al. Reproducibility of measurement of apparent diffusion coefficients of malignant hepatic tumors: effect of DWI techniques and calculation methods. J Magn Reson Imaging 2012; 36:1131-1138
126. Padhani AR. Dynamic contrast-enhanced MRI studies in human tumours. Br J Radiol 1999; 72:427-431
127. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002; 16:407-422
128. Parker GJ, Suckling J, Tanner SF, et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 1997; 7:564-574
129. Petralia G, Summers P, Viotti S, Montefrancesco R, Raimondi S, Bellomi M. Quantification of variability in breath-hold perfusion CT of hepatocellular carcinoma: a step toward clinical use. Radiology 2012; 265:448-456
130. Stewart EE, Sun H, Chen X, et al. Effect of an angiogenesis inhibitor on hepatic tumor perfusion and the implications for adjuvant cytotoxic therapy. Radiology 2012; 264:68-77
131. Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 2007; 243:736-743
132. Ippolito D, Sironi S, Pozzi M, et al. Perfusion computed tomographic assessment of early hepatocellular carcinoma in cirrhotic liver disease: initial observations. J Comput Assist Tomogr 2008; 32:855-858
133. Ippolito D, Sironi S, Pozzi M, et al. Perfusion CT in cirrhotic patients with early stage hepatocellular carcinoma: assessment of tumor-related vascularization. Eur J Radiol 2010; 73:148-152
134. Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012; 47:11-17
135. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21:3955-3964
136. Wang J, Chen LT, Tsang YM, Liu TW, Shih TT. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR 2004; 183:713-719
137. Totman JJ, O'Gorman RL, Kane PA, Karani JB. Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. Br J Radiol 2005; 78:105-109
138. Miyazaki K, Collins DJ, Walker-Samuel S, et al. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 2008; 18:1414-1421
139. Abdullah SS, Pialat JB, Wiart M, et al. Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI. J Magn Reson Imaging 2008; 28:390-395
140. Jarnagin WR, Schwartz LH, Gultekin DH, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009; 20:1589-1595
141. Yopp AC, Schwartz LH, Kemeny N, et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 2011; 18:2192-2199
142. Wang D, Gaba RC, Jin B, et al. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Acad Radiol 2011; 18:828-836
143. Taouli B, Johnson RS, Hajdu C, et al. Hepatocellular carcinoma: perfusion quantification with 3D perfusion-weighted MR imaging. AJR 2013 (in press)
144. Thng CH, Koh TS, Collins DJ, Koh DM. Perfusion magnetic resonance imaging of the liver. World J Gastroenterol 2010; 16:1598-1609